Sanofi’s Dengue Vaccine Scores Marketing Authorization in Mexico

Sanofi Pasteur has scored marketing authorization for Dengvaxia in Mexico for the prevention of dengue. It is the first vaccine to be licensed in the world for the prevention of dengue, according to the unit of pharma titan Sanofi.

The country’s Federal Commission for the Protection against Sanitary Risks approved the vaccine for the prevention of disease caused by all four dengue virus serotypes in patients between the ages of 9 and 45 living in endemic areas.

Dengvaxia’s approval was based on a global clinical program involving 40,000 subjects. Regulatory review processes for the vaccine continue in other endemic countries, and the first doses already have been produced. Sanofi expects to file 20 applications globally by year end.